目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞...目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞模型。MTT检测CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系生长的影响,流式细胞仪检测两组细胞的凋亡情况,Transwell实验检测细胞侵袭能力改变。结果:CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系在形态学方面与对照组相比无特异性改变。CXCL12作用组失巢凋亡抵抗细胞增殖能力低于对照组,凋亡率增加,侵袭能力增加,穿过膜细胞数明显高于对照组(28±3.0 vs 15±2.4,P<0.05)。结论:在人乳腺癌高转移细胞系MDA-MB-435失巢凋亡过程中,CXCL12能在一定程度上抑制失巢凋亡抵抗细胞的生长,但却能增加存活肿瘤细胞的侵袭性。展开更多
目的分离乳腺癌细胞MDA-MB-435s中的侧群细胞(sidepopulation cells,SP),并比较侧群细胞和非侧群细胞(non-side population cells,NSP)的基本生物学特点.方法经Hoechst33342染色后,利用流式细胞技术分选乳腺癌细胞MDA-MB-435s中SP和NSP ...目的分离乳腺癌细胞MDA-MB-435s中的侧群细胞(sidepopulation cells,SP),并比较侧群细胞和非侧群细胞(non-side population cells,NSP)的基本生物学特点.方法经Hoechst33342染色后,利用流式细胞技术分选乳腺癌细胞MDA-MB-435s中SP和NSP 2个细胞亚群,比较2群细胞的形态、增殖和周期等特点.结果分选得到的SP细胞约占5.2%,其增殖速度较NSP细胞快,且细胞形态较粗大.NSP细胞的G1期所占比例为73.63%,高于SP细胞的G1期所占比例为54.16%.结论 SP和NSP细胞的形态有差异,SP细胞的增殖速度快于NSP细胞,NSP细胞的周期阻滞在G1期,提示SP细胞可能在乳腺癌细胞的生长过程中具有重要的作用.展开更多
Objective:To explore the effect of “Runing Ⅱ” on the tumor growth and metastasis of Human Breast Cancer Cell Line MDA MB 435 in Vivo and Vitro. Methods: Both in vitro and in Vivo experiments were conducted in the s...Objective:To explore the effect of “Runing Ⅱ” on the tumor growth and metastasis of Human Breast Cancer Cell Line MDA MB 435 in Vivo and Vitro. Methods: Both in vitro and in Vivo experiments were conducted in the study. In Vitro, MTT method was used to detect the ability killing the tumor cells of serum with “Runing Ⅱ”. In vivo, We have observed the effect of “Runing Ⅱ” on the tumor growth and metastasis by nude mice model implanted MDA MB 435. Result: At the dosages of 32g, 16g and 8g per kilogram, “Runing Ⅱ” could kill MDA MB 435 cells 35 88%、29 84% and 8 30% respectively in vitro, the inhibitory effect of tumor growth was statistially significant, as compared with that of the normal group ( P <0 05),there were no statistital difference between the “Runing Ⅱ” group at the dosages of 48g/kg and the CTX group ( P>0 05 ). In the case of animal experiments, the Human Breast Cancer Cell Line MDA MB 435 was inoculated into the m.f.p. of nude mice, the results demonstrated that the growth suppression rate and the Lung metastasis inhibiting rate of “Runing Ⅱ” at the dosages of 48g/kg was 53 64% and 27% respectively, which were no statistial difference than that of CTX group (the growth suppression rate and the Lung metastasis inhibiting rate was 48 8% and 25 2% respectively)( P> 0 05). Conclusion: The results suggest that “Runing Ⅱ” can suppress the tumor growth and metastasis of Human Breast Cancer Cell Line MDA MB 435.展开更多
文摘目的:研究趋化因子CXCL12对人乳腺癌高转移细胞系MDA-MB-435失巢凋亡的影响。方法:实验组培养基中加入终浓度为50ng/ml的CXCL12,对照组为无CXCL12的DMEM培养基。两组细胞悬浮培养,建立人乳腺癌高转移细胞系MDA-MB-435失巢凋亡抵抗细胞模型。MTT检测CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系生长的影响,流式细胞仪检测两组细胞的凋亡情况,Transwell实验检测细胞侵袭能力改变。结果:CXCL12对于失巢凋亡抵抗MDA-MB-435细胞系在形态学方面与对照组相比无特异性改变。CXCL12作用组失巢凋亡抵抗细胞增殖能力低于对照组,凋亡率增加,侵袭能力增加,穿过膜细胞数明显高于对照组(28±3.0 vs 15±2.4,P<0.05)。结论:在人乳腺癌高转移细胞系MDA-MB-435失巢凋亡过程中,CXCL12能在一定程度上抑制失巢凋亡抵抗细胞的生长,但却能增加存活肿瘤细胞的侵袭性。
文摘Objective:To explore the effect of “Runing Ⅱ” on the tumor growth and metastasis of Human Breast Cancer Cell Line MDA MB 435 in Vivo and Vitro. Methods: Both in vitro and in Vivo experiments were conducted in the study. In Vitro, MTT method was used to detect the ability killing the tumor cells of serum with “Runing Ⅱ”. In vivo, We have observed the effect of “Runing Ⅱ” on the tumor growth and metastasis by nude mice model implanted MDA MB 435. Result: At the dosages of 32g, 16g and 8g per kilogram, “Runing Ⅱ” could kill MDA MB 435 cells 35 88%、29 84% and 8 30% respectively in vitro, the inhibitory effect of tumor growth was statistially significant, as compared with that of the normal group ( P <0 05),there were no statistital difference between the “Runing Ⅱ” group at the dosages of 48g/kg and the CTX group ( P>0 05 ). In the case of animal experiments, the Human Breast Cancer Cell Line MDA MB 435 was inoculated into the m.f.p. of nude mice, the results demonstrated that the growth suppression rate and the Lung metastasis inhibiting rate of “Runing Ⅱ” at the dosages of 48g/kg was 53 64% and 27% respectively, which were no statistial difference than that of CTX group (the growth suppression rate and the Lung metastasis inhibiting rate was 48 8% and 25 2% respectively)( P> 0 05). Conclusion: The results suggest that “Runing Ⅱ” can suppress the tumor growth and metastasis of Human Breast Cancer Cell Line MDA MB 435.
